日本发现法莫替丁能够延缓慢性心脏功能衰竭

 
 
根据一项最新研究发现，一种用于治疗烧心、返酸的非处方药物，有助于降低慢性心脏功能衰竭(CHF)的不良后果。

日本国立心血管中心(NCVC, Suita, Japan)的研究人员进行了一项前瞻性临床研究，涉及25例患有CHF和胃食管反流病(GERD)的患者，给予法莫替丁，这是一种组织胺h(2)阻滞剂，用于治疗烧心症状；另外25例患者给予另外一种治疗烧心的药物替普瑞酮，该药能够通过分泌更多的粘液来包被和保护胃免受过多的胃酸损害。

24周之后，研究人员发现那些每日服用30mg法莫替丁的患者CHF的症状较轻。左心室舒张末和收缩末长度(LVDd和LVDs)、血浆B型促尿钠肽(BNP)水平与未改变片断缩短(FS)都有所下降。由于CHF导致的再次入院率在服用法莫替丁组明显下降。与此相对照的是，替普瑞酮对CHF没有作用。所有的患者都经过3位独立心血管医生的检查，这些医生并不知道治疗方案，以确保无偏倚的检查结果。这些研究结果发表在2006年10月3日《美国心脏病学期刊》之上。

 
Heartburn Drug Slows Chronic Heart Failure
 
An over-the-counter medication used to treat heartburn and acid reflux also appears to help decrease the debilitating effects of chronic heart failure (CHF), according to a new study.

Researchers at the Japanese National Cardiovascular Center (NCVC, Suita, Japan) conducted a prospective study in which 25 patients with both CHF and gastroesophageal reflux disease (GERD) were given famotidine, a histamine h(2) blocker used to treat heartburn, and 25 patients were given an alternate heartburn medication called teprenone, which works by causing the stomach to secret more mucous to coat and protect itself against excess acid.
 
After 24 weeks, the researchers discovered that those patients receiving 30 mg doses of famotidine each day were displaying less-severe symptoms of CHF. Both left ventricular end-diastolic and end-systolic lengths (LVDd and LVDs, respectively) and the plasma B-type natriuretic peptide (BNP) levels with unaltered fractional shortening (FS) were decreased. The frequency of re-admission because of worsening of CHF was lower in the famotidine group. In contrast, teprenone had no effects on CHF. All patients were examined by three independent cardiologists who were unaware of the treatment protocols to ensure unbiased results. The results of the study were published in the October 3, 2006, edition of the Journal of the American College of Cardiology.